Incyte Corp Drug Patent Portfolio
Incyte Corp owns 3 orange book drugs protected by 39 US patents Given below is the list of Incyte Corp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11602536 | Topical treatment of vitiligo by a JAK inhibitor | 05 May, 2041 | Active |
| US11510923 | Ruxolitinib formulation for reduction of itch in atopic dermatitis | 04 Sep, 2040 | Active |
| US11590137 | Ruxolitinib formulation for reduction of itch in atopic dermatitis | 04 Sep, 2040 | Active |
| US11628162 | Methods of treating cancer with an FGFR inhibitor | 30 Aug, 2040 | Active |
| US11590138 | Topical treatment of vitiligo by a jak inhibitor | 10 Jun, 2040 | Active |
| US11466004 | Solid forms of an FGFR inhibitor and processes for preparing the same | 03 May, 2039 | Active |
| US9611267 | Substituted tricyclic compounds as FGFR inhibitors | 30 Jan, 2035 | Active |
| US10131667 | Substituted tricyclic compounds as FGFR inhibitors | 12 Jun, 2033 | Active |
| US10758543 | Topical formulation for a JAK inhibitor | 20 Nov, 2031 | Active |
| US10869870 | Topical formulation for a JAK inhibitor | 20 Nov, 2031 | Active |
| US11219624 | Topical formulation for a JAK inhibitor | 20 Nov, 2031 | Active |
| US10758543 | Topical formulation for a JAK inhibitor | 20 May, 2031 | Active |
| US10869870 | Topical formulation for a JAK inhibitor | 20 May, 2031 | Active |
| US11219624 | Topical formulation for a JAK inhibitor | 20 May, 2031 | Active |
| US11571425 | Topical formulation for a JAK inhibitor | 20 May, 2031 | Active |
| US11590136 | Topical formulation for a JAK inhibitor | 20 May, 2031 | Active |
| US10016429 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Dec, 2028 | Active |
| US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Dec, 2028 | Active |
| US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Dec, 2028 | Active |
| US8829013 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Dec, 2028 | Active |
| US10610530 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Dec, 2028 | Active |
| US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | 24 Jun, 2028 | Active |
| US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | 24 Jun, 2028 | Active |
| US10016429 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Jun, 2028 | Active |
| US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Jun, 2028 | Active |
| US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Jun, 2028 | Active |
| US8829013 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Jun, 2028 | Active |
| US10610530 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | 12 Jun, 2028 | Active |
| US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | 24 Dec, 2027 | Active |
| US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | 24 Dec, 2027 | Active |
| US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | 12 Jun, 2027 | Active |
| US9814722 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | 12 Jun, 2027 | Active |
| US10639310 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | 12 Jun, 2027 | Active |
| US9974790 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | 12 Jun, 2027 | Active |
| US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | 12 Dec, 2026 | Active |
| US9662335 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | 12 Dec, 2026 | Active |
| US9814722 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | 12 Dec, 2026 | Active |
| US10639310 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | 12 Dec, 2026 | Active |
| US9974790 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | 12 Dec, 2026 | Active |
Latest Legal Activities on Incyte Corp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Incyte Corp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jun, 2024 | US10869870 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Mar, 2024 | US10758543 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US9611267 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US10131667 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US10131667 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US9611267 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Nov, 2023 | US10639310 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Sep, 2023 | US10610530 |
|
Email Notification
Critical
| 19 May, 2023 | US11628162 |
|
Electronic Review
Critical
| 19 May, 2023 | US11628162 |
| Mail Miscellaneous Communication to Applicant | 18 May, 2023 | US11628162 |
| Miscellaneous Communication to Applicant - No Action Count | 18 May, 2023 | US11628162 |
|
Electronic Review
Critical
| 17 May, 2023 | US11602536 |
| Post Issue Communication - Certificate of Correction | 26 Apr, 2023 | US11602536 |
| Mail Miscellaneous Communication to Applicant | 21 Apr, 2023 | US11628162 |
Incyte Corp's Drug Patent Litigations
Incyte Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 27, 2017, against patent number US9662335. The petitioner Concert Pharmaceuticals, Inc., challenged the validity of this patent, with Incyte Corporation as the respondent. Click below to track the latest information on how companies are challenging Incyte Corp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9662335 | June, 2017 |
Terminated-Denied
(11 Jan, 2018)
| Incyte Corporation | Concert Pharmaceuticals, Inc. |
Incyte Corp Drug Patents' Oppositions Filed in EPO
Incyte Corp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 21, 2012, by Fresenius Kabi Deutschland Gmbh. This opposition was filed on patent number EP06839328A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16152794A | Sep, 2019 | Generics (UK) Ltd | Revoked |
| EP16197502A | Jun, 2019 | Concert Pharmaceuticals, Inc. | Granted and Under Opposition |
| EP08770794A | Dec, 2014 | Actavis Group PTC ehf | Patent maintained as amended |
| EP08770794A | Dec, 2014 | Generics [UK] Ltd (trading as Mylan) | Patent maintained as amended |
| EP06839328A | Jun, 2012 | Fresenius Kabi Deutschland GmbH | Opposition procedure closed |
Incyte Corp's Family Patents
Incyte Corp drugs have patent protection in a total of 50 countries. It's US patent count contributes only to 19.2% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Incyte Corp Drug List
Given below is the complete list of Incyte Corp's drugs and the patents protecting them.
1. Jakafi
Jakafi is protected by 17 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10016429
(Pediatric)
| Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US8722693
(Pediatric)
| Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US8822481
(Pediatric)
| Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US8829013
(Pediatric)
| Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US7598257
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
24 Jun, 2028
(3 years from now)
| Active |
| US8415362
(Pediatric)
| Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
24 Jun, 2028
(3 years from now)
| Active |
| US10016429 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US8829013 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
24 Dec, 2027
(2 years from now)
| Active |
| US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
24 Dec, 2027
(2 years from now)
| Active |
| US9079912
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
12 Jun, 2027
(2 years from now)
| Active |
| US9814722
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
12 Jun, 2027
(2 years from now)
| Active |
| US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
12 Dec, 2026
(1 year, 7 months from now)
| Active |
| US9662335 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
12 Dec, 2026
(1 year, 7 months from now)
| Active |
| US9814722 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
12 Dec, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jakafi's drug page
2. Opzelura
Opzelura is protected by 28 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11602536 | Topical treatment of vitiligo by a JAK inhibitor |
05 May, 2041
(16 years from now)
| Active |
| US11510923 | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
04 Sep, 2040
(15 years from now)
| Active |
| US11590137 | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
04 Sep, 2040
(15 years from now)
| Active |
| US11590138 | Topical treatment of vitiligo by a jak inhibitor |
10 Jun, 2040
(15 years from now)
| Active |
| US10758543
(Pediatric)
| Topical formulation for a JAK inhibitor |
20 Nov, 2031
(6 years from now)
| Active |
| US10869870
(Pediatric)
| Topical formulation for a JAK inhibitor |
20 Nov, 2031
(6 years from now)
| Active |
| US11219624
(Pediatric)
| Topical formulation for a JAK inhibitor |
20 Nov, 2031
(6 years from now)
| Active |
| US10758543 | Topical formulation for a JAK inhibitor |
20 May, 2031
(6 years from now)
| Active |
| US10869870 | Topical formulation for a JAK inhibitor |
20 May, 2031
(6 years from now)
| Active |
| US11219624 | Topical formulation for a JAK inhibitor |
20 May, 2031
(6 years from now)
| Active |
| US11571425 | Topical formulation for a JAK inhibitor |
20 May, 2031
(6 years from now)
| Active |
| US11590136 | Topical formulation for a JAK inhibitor |
20 May, 2031
(6 years from now)
| Active |
| US10610530
(Pediatric)
| Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US8722693
(Pediatric)
| Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US8822481
(Pediatric)
| Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Dec, 2028
(3 years from now)
| Active |
| US7598257
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
24 Jun, 2028
(3 years from now)
| Active |
| US8415362
(Pediatric)
| Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
24 Jun, 2028
(3 years from now)
| Active |
| US10610530 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
12 Jun, 2028
(3 years from now)
| Active |
| US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
24 Dec, 2027
(2 years from now)
| Active |
| US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
24 Dec, 2027
(2 years from now)
| Active |
| US10639310
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
12 Jun, 2027
(2 years from now)
| Active |
| US9079912
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
12 Jun, 2027
(2 years from now)
| Active |
| US9974790
(Pediatric)
| Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
12 Jun, 2027
(2 years from now)
| Active |
| US10639310 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
12 Dec, 2026
(1 year, 7 months from now)
| Active |
| US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
12 Dec, 2026
(1 year, 7 months from now)
| Active |
| US9974790 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
12 Dec, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opzelura's drug page
3. Pemazyre
Pemazyre is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11628162 | Methods of treating cancer with an FGFR inhibitor |
30 Aug, 2040
(15 years from now)
| Active |
| US11466004 | Solid forms of an FGFR inhibitor and processes for preparing the same |
03 May, 2039
(14 years from now)
| Active |
| US9611267 | Substituted tricyclic compounds as FGFR inhibitors |
30 Jan, 2035
(9 years from now)
| Active |
| US10131667 | Substituted tricyclic compounds as FGFR inhibitors |
12 Jun, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pemazyre's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List